C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/15/24
C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 01/10/24
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation MedicinesGlobeNewsWire • 01/09/24
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta PharmaceuticalsGlobeNewsWire • 01/04/24
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/24
Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High?Zacks Investment Research • 01/01/24
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a BetZacks Investment Research • 12/15/23
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 12/12/23
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)GlobeNewsWire • 12/12/23
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 11/28/23
Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom FishingZacks Investment Research • 11/13/23
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/01/23
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple MyelomGlobeNewsWire • 10/11/23
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/23
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/08/23
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/15/23